Chapter 22 The Lymphatic System, Nonspecific Resistance to
... Natural killer cells and Phagocytosis Inflammation Fever ...
... Natural killer cells and Phagocytosis Inflammation Fever ...
Contribution of myeloid and lymphoid host cells to the curative
... ingestion of tumor cell remnants. Acting as APCs, and directed by PDT-induced stimulatory and accessory signaling, these macrophages may process peptides from ingested cancer cells and present them on their membranes in the context of MHC molecules. This will enable the recognition of tumor antigens ...
... ingestion of tumor cell remnants. Acting as APCs, and directed by PDT-induced stimulatory and accessory signaling, these macrophages may process peptides from ingested cancer cells and present them on their membranes in the context of MHC molecules. This will enable the recognition of tumor antigens ...
B cells - School of Medicine
... Ankersmit HJ, et al. Am J Transplant. 2003;3:743. Bourdage JS, et al. Transplantation. 1995;59:1194. Michallet M-C, et al. Transplantation. 2003;75:657. Monti P, et al. Int Immunopharmacol. 2003;3:189. Pistillo MP, et al. Transplantation. 2002;73:1295. Préville X, et al. Transplantation. 2001;71:460 ...
... Ankersmit HJ, et al. Am J Transplant. 2003;3:743. Bourdage JS, et al. Transplantation. 1995;59:1194. Michallet M-C, et al. Transplantation. 2003;75:657. Monti P, et al. Int Immunopharmacol. 2003;3:189. Pistillo MP, et al. Transplantation. 2002;73:1295. Préville X, et al. Transplantation. 2001;71:460 ...
Autoimmune Disease
... antibodies have not been identified Autoantibodies that have been found have not been shown to have any direct pathogenic effects on exocrine tissues There is substantial circumstantial evidence that tissue damage is the result of autoimmunity ...
... antibodies have not been identified Autoantibodies that have been found have not been shown to have any direct pathogenic effects on exocrine tissues There is substantial circumstantial evidence that tissue damage is the result of autoimmunity ...
Innate Immune system
... complex (MHC) proteins -MHC presents the peptide to the T-cell receptor in a process called antigen presentation -T-cells only recognize peptides in the presence of MHC -Antigen recognition by T-cells is said to be MHC restricted and T cells must be histocompatible to be activated ...
... complex (MHC) proteins -MHC presents the peptide to the T-cell receptor in a process called antigen presentation -T-cells only recognize peptides in the presence of MHC -Antigen recognition by T-cells is said to be MHC restricted and T cells must be histocompatible to be activated ...
immune-mediated anemia
... Accelerated destruction or removal of red-blood cells related to an immune response, in which the body produces antibodies against red-blood cells Also known as “immune-mediated hemolytic anemia” or “IMHA” “Anemia” is a low red-blood cell count; “hemolytic” refers to hemolysis; “hemolysis” is ...
... Accelerated destruction or removal of red-blood cells related to an immune response, in which the body produces antibodies against red-blood cells Also known as “immune-mediated hemolytic anemia” or “IMHA” “Anemia” is a low red-blood cell count; “hemolytic” refers to hemolysis; “hemolysis” is ...
See presentation #4
... • Grown from BM mononuclear cells by their adherence to plastic in tissue culture flasks ...
... • Grown from BM mononuclear cells by their adherence to plastic in tissue culture flasks ...
Transplantation and Rejection
... • There are more than 30 gene loci • Reject at different rate • In human known as human leucocyte antigens (HLA) • Cellular constituents are called minor histocompatibility antigens • These induce rejection at a slower rate • Combination of several minor antigens induce strong rejection ...
... • There are more than 30 gene loci • Reject at different rate • In human known as human leucocyte antigens (HLA) • Cellular constituents are called minor histocompatibility antigens • These induce rejection at a slower rate • Combination of several minor antigens induce strong rejection ...
Lymph Nodes
... • T cells and B cells protect against antigens – Anything body perceives as foreign • Bacteria and bacterial toxins, viruses, mismatched RBCs, cancer cells ...
... • T cells and B cells protect against antigens – Anything body perceives as foreign • Bacteria and bacterial toxins, viruses, mismatched RBCs, cancer cells ...
B cell development, selection and maturation
... 2. B cell development begins by rearrangement of the heavy-chain locus 3. The pre-B-cell receptor (pBCR) tests for successful production of a complete heavy chain 4. pBCR signals proliferation of late pro-B cells, “licenses” pre-B transit 5. Pre-B cells rearrange the Ig light chain loci IMMATURE B C ...
... 2. B cell development begins by rearrangement of the heavy-chain locus 3. The pre-B-cell receptor (pBCR) tests for successful production of a complete heavy chain 4. pBCR signals proliferation of late pro-B cells, “licenses” pre-B transit 5. Pre-B cells rearrange the Ig light chain loci IMMATURE B C ...
Using nCounter® RNA:Protein Profiling Technology
... permits surveillance of these key regulatory elements via both gene expression and proteomic markers (FIGURE 2 and TABLE 1). It has been shown that cancer therapy response rates may be improved by modulating the tumor microenvironment toward a state that is more supportive of immune function via sev ...
... permits surveillance of these key regulatory elements via both gene expression and proteomic markers (FIGURE 2 and TABLE 1). It has been shown that cancer therapy response rates may be improved by modulating the tumor microenvironment toward a state that is more supportive of immune function via sev ...
NATIONAL CHENG KUNG UNIVERSITY MEDICAL COLLEGE
... cortex (B cell area) -- closely packed clusters of lymphocytes forming nodules of follicles. Sometimes called the T-independent area. Contains mostly B cells. When an immune response takes place, the follicles develop a central area with large proliferating cells termed a germinal center. [Fig. 2.4 ...
... cortex (B cell area) -- closely packed clusters of lymphocytes forming nodules of follicles. Sometimes called the T-independent area. Contains mostly B cells. When an immune response takes place, the follicles develop a central area with large proliferating cells termed a germinal center. [Fig. 2.4 ...
AntibodyNoTP
... Antibodies as Antigens Why does this matters? If we want to use antibodies as therapeutic agents in patients, we have to understand and control the immunogenicity of the antibodies, or they will generate damaging and dangerous allergic responses, and be cleared from the patient and would be ineffec ...
... Antibodies as Antigens Why does this matters? If we want to use antibodies as therapeutic agents in patients, we have to understand and control the immunogenicity of the antibodies, or they will generate damaging and dangerous allergic responses, and be cleared from the patient and would be ineffec ...
Document
... as innate immunity, and sometimes as acquired immunity What is the difference within the macrophages? (when are they considered as innate, and when as 4) About the phagoctose process: what are ROI and NO? Aren't lysosomes enough to "digest" the antigen? ...
... as innate immunity, and sometimes as acquired immunity What is the difference within the macrophages? (when are they considered as innate, and when as 4) About the phagoctose process: what are ROI and NO? Aren't lysosomes enough to "digest" the antigen? ...
Unit 14
... B-cell begins to produce antibodies. Antibodies are proteins that are specifically shaped to bind to the antigen and mark the antigen for destruction. b. The second type of B-cell is a memory B-cell. A memory Bcell will genetically “remember” the correct antibody. Then, if you are exposed to the s ...
... B-cell begins to produce antibodies. Antibodies are proteins that are specifically shaped to bind to the antigen and mark the antigen for destruction. b. The second type of B-cell is a memory B-cell. A memory Bcell will genetically “remember” the correct antibody. Then, if you are exposed to the s ...
File
... Compare and contrast active and passive humoral immunity. • Active humoral immunity occurs when B cells encounter antigens and produce specific antibodies against them • Two types of active humoral immunity 1. Naturally acquired: formed in response to actual bacterial or viral infection 2. Artific ...
... Compare and contrast active and passive humoral immunity. • Active humoral immunity occurs when B cells encounter antigens and produce specific antibodies against them • Two types of active humoral immunity 1. Naturally acquired: formed in response to actual bacterial or viral infection 2. Artific ...
CISBIC March 09 - Workspace
... CISBIC, Flowers Building, Imperial College London. www.imperial.ac.uk/cisbic ...
... CISBIC, Flowers Building, Imperial College London. www.imperial.ac.uk/cisbic ...
AIDS and its Effect on the Immune Response
... AIDS and its Effect on the Immune Response Acquired Immune Deficiency Syndrome (AIDS) is a disease that results in the destruction of an individual’s immune system. The virus that causes AIDS is passed from an infected individual to another person by means of body fluids such as blood, semen, or vag ...
... AIDS and its Effect on the Immune Response Acquired Immune Deficiency Syndrome (AIDS) is a disease that results in the destruction of an individual’s immune system. The virus that causes AIDS is passed from an infected individual to another person by means of body fluids such as blood, semen, or vag ...
Immune System - Trimble County Schools
... Natural killer cells Antimicrobial proteins Inflammatory response Humoral response: ...
... Natural killer cells Antimicrobial proteins Inflammatory response Humoral response: ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.